Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Ondansetron for Adjunctive Therapy in OCD
NCT01275248Phase 2Terminated
- Sponsor
- Transcept Pharmaceuticals
- Start
- Jan 2011
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ondansetron in obsessive compulsive disorder (OCD), sponsored by Transcept Pharmaceuticals. Started Jan 2011; status: terminated.
02
Drugs
ondansetron
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT01275248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01275248.